| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| eIF-2 Kinase | 14 | 2022 | 49 | 2.690 |
Why?
|
| Unfolded Protein Response | 13 | 2022 | 70 | 1.630 |
Why?
|
| Protein Kinase Inhibitors | 7 | 2021 | 331 | 0.990 |
Why?
|
| DNA Repair | 9 | 2019 | 127 | 0.900 |
Why?
|
| Protein-Tyrosine Kinases | 7 | 2010 | 195 | 0.850 |
Why?
|
| Endoplasmic Reticulum Stress | 10 | 2022 | 99 | 0.790 |
Why?
|
| Proto-Oncogene Proteins B-raf | 2 | 2016 | 25 | 0.680 |
Why?
|
| Tumor Suppressor Proteins | 2 | 2016 | 194 | 0.620 |
Why?
|
| Small Molecule Libraries | 4 | 2020 | 53 | 0.590 |
Why?
|
| Signal Transduction | 14 | 2022 | 2689 | 0.590 |
Why?
|
| Glaucoma, Open-Angle | 4 | 2021 | 19 | 0.570 |
Why?
|
| Melanoma | 2 | 2016 | 335 | 0.520 |
Why?
|
| Drug Discovery | 2 | 2019 | 94 | 0.470 |
Why?
|
| Apoptosis | 13 | 2022 | 1641 | 0.470 |
Why?
|
| High-Throughput Screening Assays | 1 | 2014 | 48 | 0.450 |
Why?
|
| Alzheimer Disease | 5 | 2020 | 565 | 0.440 |
Why?
|
| Neurodegenerative Diseases | 4 | 2020 | 102 | 0.440 |
Why?
|
| Antineoplastic Agents | 8 | 2020 | 1070 | 0.400 |
Why?
|
| DNA Damage | 7 | 2021 | 190 | 0.400 |
Why?
|
| Pyrimidines | 4 | 2006 | 178 | 0.390 |
Why?
|
| Fusion Proteins, bcr-abl | 3 | 2010 | 37 | 0.380 |
Why?
|
| Piperazines | 4 | 2006 | 206 | 0.380 |
Why?
|
| Enzyme Inhibitors | 1 | 2014 | 659 | 0.370 |
Why?
|
| Colorectal Neoplasms | 3 | 2022 | 561 | 0.360 |
Why?
|
| Neoplasms | 6 | 2019 | 1667 | 0.350 |
Why?
|
| Endoplasmic Reticulum | 5 | 2019 | 148 | 0.330 |
Why?
|
| Antibiotics, Antineoplastic | 2 | 2006 | 82 | 0.330 |
Why?
|
| Uracil-DNA Glycosidase | 1 | 2008 | 17 | 0.300 |
Why?
|
| Leuzea | 2 | 2017 | 2 | 0.300 |
Why?
|
| Oils, Volatile | 2 | 2017 | 9 | 0.290 |
Why?
|
| Cell Transformation, Neoplastic | 2 | 2019 | 235 | 0.280 |
Why?
|
| Idarubicin | 1 | 2006 | 4 | 0.280 |
Why?
|
| Adenocarcinoma | 2 | 2020 | 475 | 0.260 |
Why?
|
| Caspase 3 | 3 | 2022 | 233 | 0.260 |
Why?
|
| Eukaryotic Initiation Factor-2 | 4 | 2021 | 17 | 0.250 |
Why?
|
| Humans | 38 | 2022 | 68618 | 0.250 |
Why?
|
| Phosphorylation | 7 | 2020 | 1200 | 0.250 |
Why?
|
| Plant Roots | 3 | 2017 | 22 | 0.220 |
Why?
|
| Cell Proliferation | 6 | 2021 | 1174 | 0.220 |
Why?
|
| DNA-Binding Proteins | 3 | 2017 | 700 | 0.220 |
Why?
|
| Heterogeneous-Nuclear Ribonucleoprotein K | 1 | 2022 | 2 | 0.220 |
Why?
|
| Cell Line, Tumor | 6 | 2017 | 1851 | 0.210 |
Why?
|
| Carbon Monoxide | 1 | 2022 | 58 | 0.200 |
Why?
|
| Carcinogenesis | 1 | 2022 | 124 | 0.200 |
Why?
|
| Reactive Oxygen Species | 3 | 2019 | 499 | 0.190 |
Why?
|
| Polymorphism, Single Nucleotide | 4 | 2017 | 627 | 0.180 |
Why?
|
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 3 | 2010 | 63 | 0.170 |
Why?
|
| Animals | 14 | 2020 | 20881 | 0.170 |
Why?
|
| Glioma | 2 | 2017 | 140 | 0.170 |
Why?
|
| Disease | 1 | 2019 | 41 | 0.170 |
Why?
|
| Oxidative Stress | 3 | 2019 | 718 | 0.160 |
Why?
|
| Cell Differentiation | 2 | 2013 | 1034 | 0.160 |
Why?
|
| Interleukin-1beta | 2 | 2016 | 88 | 0.160 |
Why?
|
| Caspase 9 | 1 | 2017 | 31 | 0.150 |
Why?
|
| Anti-Inflammatory Agents | 2 | 2017 | 234 | 0.150 |
Why?
|
| MicroRNAs | 2 | 2013 | 447 | 0.150 |
Why?
|
| Membrane Potential, Mitochondrial | 1 | 2017 | 93 | 0.150 |
Why?
|
| Amyloid beta-Peptides | 1 | 2019 | 191 | 0.150 |
Why?
|
| Leonurus | 1 | 2017 | 2 | 0.140 |
Why?
|
| Xeroderma Pigmentosum Group D Protein | 1 | 2017 | 3 | 0.140 |
Why?
|
| Mice | 8 | 2019 | 8474 | 0.140 |
Why?
|
| Plant Oils | 1 | 2017 | 31 | 0.140 |
Why?
|
| Haploinsufficiency | 1 | 2016 | 14 | 0.140 |
Why?
|
| Cell Cycle Checkpoints | 1 | 2016 | 37 | 0.140 |
Why?
|
| Gene Dosage | 1 | 2016 | 47 | 0.140 |
Why?
|
| Plant Extracts | 1 | 2017 | 122 | 0.140 |
Why?
|
| Cell Cycle | 3 | 2020 | 312 | 0.140 |
Why?
|
| Neuroblastoma | 1 | 2017 | 109 | 0.140 |
Why?
|
| Neuroglia | 1 | 2017 | 136 | 0.130 |
Why?
|
| Neuroprotective Agents | 1 | 2019 | 317 | 0.130 |
Why?
|
| Matrix Metalloproteinase 12 | 1 | 2015 | 31 | 0.130 |
Why?
|
| Tissue Inhibitor of Metalloproteinase-1 | 1 | 2015 | 59 | 0.130 |
Why?
|
| Matrix Metalloproteinase 1 | 1 | 2015 | 74 | 0.120 |
Why?
|
| Anti-Infective Agents | 1 | 2016 | 166 | 0.120 |
Why?
|
| HSP70 Heat-Shock Proteins | 1 | 2015 | 42 | 0.120 |
Why?
|
| Breast | 1 | 2015 | 137 | 0.120 |
Why?
|
| Apolipoproteins E | 1 | 2015 | 92 | 0.120 |
Why?
|
| Imatinib Mesylate | 4 | 2006 | 26 | 0.120 |
Why?
|
| Matrix Metalloproteinase 9 | 1 | 2015 | 160 | 0.120 |
Why?
|
| Diacylglycerol Kinase | 1 | 2013 | 8 | 0.120 |
Why?
|
| Brain Neoplasms | 1 | 2017 | 371 | 0.110 |
Why?
|
| Fluorescence Resonance Energy Transfer | 1 | 2014 | 45 | 0.110 |
Why?
|
| Brain-Derived Neurotrophic Factor | 1 | 2015 | 124 | 0.110 |
Why?
|
| F-Box Proteins | 1 | 2013 | 14 | 0.110 |
Why?
|
| Cell Line | 4 | 2021 | 1752 | 0.110 |
Why?
|
| Genotype | 4 | 2017 | 786 | 0.110 |
Why?
|
| Drug Design | 1 | 2014 | 107 | 0.110 |
Why?
|
| Benzamides | 4 | 2006 | 156 | 0.110 |
Why?
|
| Receptors, Antigen, T-Cell | 1 | 2013 | 135 | 0.110 |
Why?
|
| ras Proteins | 1 | 2013 | 102 | 0.110 |
Why?
|
| Receptors, N-Methyl-D-Aspartate | 1 | 2015 | 266 | 0.110 |
Why?
|
| Transcription Factor CHOP | 1 | 2012 | 28 | 0.110 |
Why?
|
| T-Lymphocytes, Regulatory | 1 | 2013 | 199 | 0.100 |
Why?
|
| Fibroblasts | 2 | 2014 | 902 | 0.100 |
Why?
|
| Adipocytes | 1 | 2012 | 88 | 0.100 |
Why?
|
| Poland | 3 | 2015 | 10 | 0.100 |
Why?
|
| Mutation | 1 | 2016 | 1213 | 0.100 |
Why?
|
| RecQ Helicases | 1 | 2010 | 1 | 0.090 |
Why?
|
| Exodeoxyribonucleases | 1 | 2010 | 8 | 0.090 |
Why?
|
| Phenotype | 1 | 2014 | 947 | 0.090 |
Why?
|
| Genomic Instability | 1 | 2010 | 41 | 0.090 |
Why?
|
| Gene Expression Regulation | 2 | 2015 | 1293 | 0.090 |
Why?
|
| Computer Simulation | 1 | 2014 | 706 | 0.090 |
Why?
|
| Drug Resistance, Neoplasm | 3 | 2007 | 332 | 0.090 |
Why?
|
| K562 Cells | 2 | 2006 | 44 | 0.090 |
Why?
|
| Ubiquitination | 2 | 2022 | 85 | 0.080 |
Why?
|
| Genetic Predisposition to Disease | 3 | 2017 | 786 | 0.080 |
Why?
|
| Disease Progression | 3 | 2019 | 1038 | 0.080 |
Why?
|
| Breast Neoplasms | 2 | 2015 | 1536 | 0.070 |
Why?
|
| Leukemia, Lymphoid | 1 | 2006 | 17 | 0.070 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2015 | 1085 | 0.070 |
Why?
|
| Microbial Sensitivity Tests | 2 | 2017 | 226 | 0.070 |
Why?
|
| Cell Survival | 3 | 2017 | 901 | 0.070 |
Why?
|
| Caspases | 1 | 2006 | 194 | 0.070 |
Why?
|
| Transcription, Genetic | 1 | 2008 | 562 | 0.070 |
Why?
|
| Risk Factors | 4 | 2017 | 5731 | 0.060 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 2 | 2017 | 507 | 0.060 |
Why?
|
| Polymorphism, Restriction Fragment Length | 2 | 2015 | 44 | 0.060 |
Why?
|
| Astrocytes | 2 | 2019 | 270 | 0.060 |
Why?
|
| Optic Disk | 2 | 2015 | 37 | 0.060 |
Why?
|
| DNA, Neoplasm | 3 | 2010 | 95 | 0.060 |
Why?
|
| Doxorubicin | 1 | 2006 | 231 | 0.060 |
Why?
|
| Head and Neck Neoplasms | 1 | 2009 | 561 | 0.060 |
Why?
|
| Enzyme Activation | 2 | 2017 | 791 | 0.060 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2017 | 710 | 0.050 |
Why?
|
| Aged | 5 | 2017 | 14862 | 0.050 |
Why?
|
| Tumor Cells, Cultured | 2 | 2020 | 852 | 0.050 |
Why?
|
| Comet Assay | 2 | 2015 | 11 | 0.050 |
Why?
|
| Oncogenes | 1 | 2022 | 71 | 0.050 |
Why?
|
| Aged, 80 and over | 3 | 2015 | 4848 | 0.050 |
Why?
|
| Kinetics | 3 | 2009 | 1047 | 0.050 |
Why?
|
| Middle Aged | 5 | 2017 | 21147 | 0.050 |
Why?
|
| Proto-Oncogene Proteins c-akt | 2 | 2013 | 331 | 0.050 |
Why?
|
| RNA-Binding Proteins | 1 | 2022 | 215 | 0.050 |
Why?
|
| Autophagy | 1 | 2022 | 208 | 0.040 |
Why?
|
| Female | 7 | 2017 | 38074 | 0.040 |
Why?
|
| Cells, Cultured | 2 | 2017 | 2673 | 0.040 |
Why?
|
| Molecular Targeted Therapy | 1 | 2020 | 170 | 0.040 |
Why?
|
| Disease Susceptibility | 1 | 2019 | 179 | 0.040 |
Why?
|
| RNA, Messenger | 1 | 2022 | 1664 | 0.040 |
Why?
|
| T-Lymphocytes | 1 | 2022 | 597 | 0.040 |
Why?
|
| Blotting, Western | 2 | 2013 | 954 | 0.040 |
Why?
|
| bcl-2-Associated X Protein | 1 | 2017 | 111 | 0.040 |
Why?
|
| Oxidation-Reduction | 1 | 2019 | 567 | 0.040 |
Why?
|
| Antineoplastic Agents, Phytogenic | 1 | 2017 | 88 | 0.040 |
Why?
|
| Enterococcus faecalis | 1 | 2016 | 6 | 0.040 |
Why?
|
| Gas Chromatography-Mass Spectrometry | 1 | 2016 | 59 | 0.040 |
Why?
|
| Treatment Outcome | 1 | 2009 | 7029 | 0.040 |
Why?
|
| Candida albicans | 1 | 2016 | 39 | 0.040 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2017 | 231 | 0.030 |
Why?
|
| Poly (ADP-Ribose) Polymerase-1 | 1 | 2015 | 7 | 0.030 |
Why?
|
| DNA Glycosylases | 1 | 2015 | 21 | 0.030 |
Why?
|
| Pseudomonas aeruginosa | 1 | 2016 | 133 | 0.030 |
Why?
|
| Male | 5 | 2017 | 37321 | 0.030 |
Why?
|
| Biomarkers, Tumor | 1 | 2019 | 508 | 0.030 |
Why?
|
| X-ray Repair Cross Complementing Protein 1 | 1 | 2015 | 7 | 0.030 |
Why?
|
| Retinal Neurons | 1 | 2015 | 9 | 0.030 |
Why?
|
| Saccharomyces cerevisiae | 1 | 2016 | 173 | 0.030 |
Why?
|
| Visual Fields | 1 | 2015 | 41 | 0.030 |
Why?
|
| Epistasis, Genetic | 1 | 2015 | 32 | 0.030 |
Why?
|
| Protein Unfolding | 1 | 2015 | 7 | 0.030 |
Why?
|
| Interleukin-6 | 1 | 2016 | 330 | 0.030 |
Why?
|
| Lipopolysaccharides | 1 | 2016 | 455 | 0.030 |
Why?
|
| Antioxidants | 1 | 2017 | 304 | 0.030 |
Why?
|
| Sequence Analysis, DNA | 1 | 2015 | 208 | 0.030 |
Why?
|
| Lymphocytes | 1 | 2015 | 228 | 0.030 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2015 | 536 | 0.030 |
Why?
|
| Alleles | 1 | 2015 | 386 | 0.030 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2016 | 626 | 0.030 |
Why?
|
| Ribosomal Protein S6 Kinases | 1 | 2013 | 17 | 0.030 |
Why?
|
| Cyclin D1 | 1 | 2013 | 37 | 0.030 |
Why?
|
| Immunoprecipitation | 1 | 2013 | 132 | 0.030 |
Why?
|
| DNA, Complementary | 1 | 2013 | 251 | 0.030 |
Why?
|
| Point Mutation | 1 | 2013 | 97 | 0.030 |
Why?
|
| Green Fluorescent Proteins | 1 | 2013 | 200 | 0.030 |
Why?
|
| Amino Acid Substitution | 1 | 2013 | 137 | 0.030 |
Why?
|
| Cloning, Molecular | 1 | 2013 | 357 | 0.030 |
Why?
|
| Thapsigargin | 1 | 2012 | 18 | 0.030 |
Why?
|
| Activating Transcription Factor 4 | 1 | 2012 | 6 | 0.030 |
Why?
|
| Extracellular Signal-Regulated MAP Kinases | 1 | 2013 | 175 | 0.030 |
Why?
|
| Methylation | 1 | 2012 | 56 | 0.030 |
Why?
|
| NIH 3T3 Cells | 1 | 2012 | 65 | 0.030 |
Why?
|
| HEK293 Cells | 1 | 2013 | 326 | 0.030 |
Why?
|
| Flow Cytometry | 1 | 2013 | 489 | 0.030 |
Why?
|
| Gene Deletion | 1 | 2013 | 235 | 0.030 |
Why?
|
| Phosphatidic Acids | 1 | 2012 | 12 | 0.030 |
Why?
|
| HeLa Cells | 1 | 2012 | 237 | 0.030 |
Why?
|
| Embryo, Mammalian | 1 | 2012 | 176 | 0.030 |
Why?
|
| Stress, Physiological | 1 | 2013 | 215 | 0.020 |
Why?
|
| Histones | 1 | 2012 | 111 | 0.020 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2015 | 756 | 0.020 |
Why?
|
| TOR Serine-Threonine Kinases | 1 | 2012 | 118 | 0.020 |
Why?
|
| Analysis of Variance | 1 | 2013 | 1040 | 0.020 |
Why?
|
| Werner Syndrome Helicase | 1 | 2010 | 1 | 0.020 |
Why?
|
| Case-Control Studies | 1 | 2015 | 1553 | 0.020 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2012 | 223 | 0.020 |
Why?
|
| Lipid Metabolism | 1 | 2012 | 186 | 0.020 |
Why?
|
| DNA Breaks, Double-Stranded | 1 | 2010 | 24 | 0.020 |
Why?
|
| Rats | 1 | 2019 | 5300 | 0.020 |
Why?
|
| Chromosome Aberrations | 1 | 2010 | 86 | 0.020 |
Why?
|
| Promoter Regions, Genetic | 1 | 2012 | 615 | 0.020 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2013 | 689 | 0.020 |
Why?
|
| Anti-Bacterial Agents | 1 | 2017 | 1026 | 0.020 |
Why?
|
| Models, Biological | 1 | 2013 | 981 | 0.020 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2010 | 376 | 0.020 |
Why?
|
| Radiotherapy | 1 | 2009 | 86 | 0.020 |
Why?
|
| Hydrogen Peroxide | 1 | 2009 | 168 | 0.020 |
Why?
|
| Cisplatin | 1 | 2009 | 192 | 0.020 |
Why?
|
| Transcription Factors | 1 | 2012 | 753 | 0.020 |
Why?
|
| Mice, Knockout | 1 | 2012 | 1692 | 0.020 |
Why?
|
| Neoplasm Metastasis | 1 | 2009 | 306 | 0.020 |
Why?
|
| Methylnitronitrosoguanidine | 1 | 2006 | 8 | 0.020 |
Why?
|
| Mitomycin | 1 | 2006 | 27 | 0.020 |
Why?
|
| Gamma Rays | 1 | 2006 | 64 | 0.020 |
Why?
|
| Adult | 2 | 2017 | 21403 | 0.020 |
Why?
|
| Drug Interactions | 1 | 2006 | 289 | 0.020 |
Why?
|
| Trastuzumab | 1 | 2005 | 17 | 0.020 |
Why?
|
| Gastrointestinal Neoplasms | 1 | 2005 | 40 | 0.020 |
Why?
|
| Receptor, ErbB-2 | 1 | 2005 | 129 | 0.010 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2009 | 629 | 0.010 |
Why?
|
| Lymphatic Metastasis | 1 | 2005 | 274 | 0.010 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2005 | 151 | 0.010 |
Why?
|
| Antibodies, Monoclonal | 1 | 2005 | 511 | 0.010 |
Why?
|